Knowledge Hub

Antibody-Drug Conjugate Pipeline Review By Target, Drug, Phase And Company

Press Release   •   Jan 31, 2017 04:24 EST

The report analyzes and presents an overview on "Antibody-Drug Conjugate Pipeline Review By Target, Drug, Phase And Company" worldwide.

The competitive intelligence report „Antibody-Drug Conjugate Pipeline Review by target, drug, phase and company“ evaluates and describes the competitive landscape of antibody-drug conjugates (ADCs) in a tabular format by target, payload, R&D phase and company as of December 2016.

Purchase of the pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

Since our last ADC Competitor Analysis in April 2013, the number of ADCs in active clinical development has doubled from 33 in 2013 to 65 at the end of the year 2016. Among them are eight ADCs in late stage development or under regulatory review. More than 20 ADCs are in the IND stage or undergoing IND-enabling studies. This analysis identified further 58 preclinical stage ADC projects and 22 ADC discovery programs. However, the number of ADCs discontinued from clinical development also has increased.

Get The Sample Copy Of This Report: http://www.marketresearchreports.biz/sample/sample/901910

The report furthermore lists the ADCs by target, drug payload, and by company portfolio.

Among the popular targets of ADC developments identified in the search are:

Her2
CD30
CD33
CD22
CD19
PSMA
5T4
EGF-R
CEACAM5
CD37
CD38
CD25
CD70
Mesothelin
c-Met
MUC16
CD123
Tissue Factor
TROP-2
FGF-R
Ephrin-A
in addition to unique targets identified by companies with proprietary target discovery programs.

With the increasing number of ADCs in development and of companies with in-house ADC technology development, new payloads are being evaluated in early clinical studies.

The report includes a compilation of currently active as well as discontinued ADC R&D. In addition, the report lists company-specific R&D pipelines of ADCs.

Competitor projects are listed in a tabular format providing information on:

Drug Codes,
Target / Mechanism of Action,
Class of Compound (antibody, linker, payload),
Company,
Product Category,
Indication,
R&D Stage and
additional comments about latest results with a hyperlink leading to the source of information.
About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

To View The Latest Industry Press Releases: http://www.marketresearchreports.biz/pressreleases

Contact
Mr. Nachiket
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-621-2074
Website: http://www.marketresearchreports.biz/
E-Mail: sales@marketresearchreports.biz
Follow us on LinkedIn: https://www.linkedin.com/company/marketresearchreports-biz
Thanks………..!!!!!!!!!!!